PDL BioPharma, Inc. (NASDAQ:PDLI) Files An 8-K Other EventsItem 8.01 Other Events.
PDL BioPharma Announces $100 Million Share Repurchase Program
On September 24, 2018, PDL BioPharma, Inc. (the Company) issued a press release regarding the Company's board of directors authorization to repurchase up to $100 million of the Company's common stock. A copy of the press release is furnished hereto as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit No. |
Description |
|
99.1 |
PDL BIOPHARMA, INC. ExhibitEX-99.1 2 pdli-201809248xkex991.htm PRESS RELEASE Exhibit Exhibit 99.1PDL BioPharma Announces New $100 Million Stock Repurchase ProgramINCLINE VILLAGE,…To view the full exhibit click here
About PDL BioPharma, Inc. (NASDAQ:PDLI)
PDL BioPharma, Inc., formerly Protein Design Labs, Inc., manages a portfolio of patents and royalty assets, consisting of its Queen et al. patents, license agreements with various biotechnology and pharmaceutical companies, and royalty and other assets acquired. The Company provides non-dilutive growth capital and financing solutions to late-stage public and private healthcare companies and offers immediate financial monetization of royalty streams to companies, academic institutions and inventors. It evaluates its investments based on the quality of the income generating assets and potential returns on investment. It is focused on intellectual property asset management, acquiring income generating assets and maximizing value for its stockholders, among others. It receives royalties on sales of over ten humanized antibody products, which include Avastin, Herceptin, Xolair, Kadcyla, Tysabri, Actemra, Gazyva and Entyvio all of which are approved for use.